Skip to content
Synopulse
  • The Brief
    • Quick
    • In Depth
    • Editor’s Pick
    • Findings
  • Reports
    • The beats
      • Catalyst
      • AccessWatch
      • DealPulse Signal
      • DealPulse Report
    • Analysis
      • The Throughline
      • The Top Line
      • The Forecast
    • Coverage
      • ShowFloor
      • The Arena
  • The Pulse
    • NeuroPulse
    • OrphanPulse
  • Topics
    • By subject
      • Deals
      • Regulatory
      • Market Access
      • Pricing & Reimbursement
      • Legal & Policy
    • By technology
      • Antibody
      • Cell & Gene Tx
      • Drug conjugates
      • AI/ML
      • Digital Health
      • Radiopharma
    • By therapy area
      • Neurology
      • Oncology
      • Rare Diseases
      • Cardio-Metabolic
      • Immunology & Inflammation
      • Orthopaedics
Four Health Systems Automated the Prior Authorization Question, Not the Answer
Four Health Systems Automated the Prior Authorization Question, Not the Answer
Athithi Verma August 19, 2026
The piece of the federal prior authorization mandate that shipped five months early is the piece that cannot deny anything.
Novartis Declines Canadian Reimbursement for Vanrafia Five Weeks After Health Canada Approved It
Novartis Declines Canadian Reimbursement for Vanrafia Five Weeks After Health Canada Approved It
CMS Comments Close on a Rule That Retires the Small Biotech Exemption and Shuts the Hyaluronidase Route
CMS Comments Close on a Rule That Retires the Small Biotech Exemption and Shuts the Hyaluronidase Route
A Third Centiloid Scale Just Cleared. The First Two Already Disagree at the Threshold.
A Third Centiloid Scale Just Cleared. The First Two Already Disagree at the Threshold.
OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later
OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later
NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard
NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard

Editor’s Pick

In Japan, Expanding a Label Is What Triggers the Price Cut

In Japan, Expanding a Label Is What Triggers the Price Cut

AstraZeneca Announced Nothing. The Market Charged It $24bn Anyway.

AstraZeneca Announced Nothing. The Market Charged It $24bn Anyway.

Congress Exempted the Medically Frail. The Coding System Cannot Find Them.

Congress Exempted the Medically Frail. The Coding System Cannot Find Them.

NeuroPulse


NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard

NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard

NeuroPulse Wk 32: Takeda Fixed the Cause, and Cannot Ship It Yet

NeuroPulse Wk 32: Takeda Fixed the Cause, and Cannot Ship It Yet

OrphanPulse


OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later

OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later

OrphanPulse Wk 32: Tarsus Paid $450M Upfront for a Readout in 2029

OrphanPulse Wk 32: Tarsus Paid $450M Upfront for a Readout in 2029

DealPulse Signal


DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Report


DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealFlow H1 2026 M&A Doubles as Upfront Spending Hits $174B

DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B

The Beats


DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

Analysis


Reshaping Pharma by 2027

7 Market Access Trends Reshaping Pharmaย by 2027

The Biologics Patent Cliff: Inside Pharma's 2026-2029 Reckoning

The Biologics Patent Cliff: Inside Pharma’s 2026-2029 Reckoning

Coverage


The ADC Decade Accelerates What to Watch at ASCO 2026

The ADC Decade Accelerates: What to Watch at ASCO 2026

The Briefs

Four Health Systems Automated the Prior Authorization Question, Not the Answer

Four Health Systems Automated the Prior Authorization Question, Not the Answer

Athithi Verma August 19, 2026
Novartis Declines Canadian Reimbursement for Vanrafia Five Weeks After Health Canada Approved It

Novartis Declines Canadian Reimbursement for Vanrafia Five Weeks After Health Canada Approved It

Athithi Verma August 19, 2026
CMS Comments Close on a Rule That Retires the Small Biotech Exemption and Shuts the Hyaluronidase Route

CMS Comments Close on a Rule That Retires the Small Biotech Exemption and Shuts the Hyaluronidase Route

Athithi Verma August 19, 2026
A Third Centiloid Scale Just Cleared. The First Two Already Disagree at the Threshold.

A Third Centiloid Scale Just Cleared. The First Two Already Disagree at the Threshold.

Athithi Verma August 19, 2026
ViGNet Reported 82.55% Discrimination Predicting Immunotherapy Response in NSCLC

ViGNet Reported 82.55% Discrimination Predicting Immunotherapy Response in NSCLC

Athithi Verma August 18, 2026
Payers Do Not Cover Wellness. In Women's Health, That Is a Naming Decision.

Payers Do Not Cover Wellness. In Women’s Health, That Is a Naming Decision.

Athithi Verma August 18, 2026
Read More
Synopulse
Contact Us

Explore Synopulse

  • NeuroPulse
  • Deals
  • Market Access
  • Industry Trends
  • Regulatory

About

  • About Synopulse
  • Contact Us
  • Announcements
© 2026 Synopulse • Built with GeneratePress